(P130) An Exploratory Pilot Study of Perfusion Patterns in Locoregionally Advanced Head and Neck Cancer Using a Novel Analysis Technique of Dynamic Contrast-Enhanced (DCE)-MRI

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

UPR is a novel technique that has been developed in a preclinical tumor model and that is potentially applicable in HNCs. This exploratory study appears consistently to identify subvolumes within the GTV that may have therapeutic implications and that may be promising areas for further research (eg, correlation with hypoxia and clinical outcome).

Jonathan Verma, MD, Radka Stoyanova, PhD, N. Andres Parra, PhD, Kyle Padgett, PhD, Michael Samuels, MD, Nagy Elsayyad, MD; University of Miami Sylvester Comprehensive Cancer Center

PURPOSE: Recently, an unsupervised pattern recognition (UPR) technique was developed by one of the investigators to analyze dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). The technique utilizes non-negative matrix factorization (NMF) and has hitherto not been studied in head and neck cancers (HNCs). This study aims at implementing this technique in HNCs in order to explore its potential value in characterizing perfusion patterns within these tumors. The presence of subvolumes in the HNC that are differentially perfused may have future therapeutic implications with respect to dose painting, intensification, or deintensification of treatment.

METHODS: Eight patients who received definitive chemoradiotherapy for locoregionally advanced HNC were randomly selected. All received 70 Gy/33–35 fractions/6–7 weeks with concurrent cisplatin. As part of the radiotherapy planning, MRI had been obtained for each patient, and DCE sequences were acquired, in addition to the usual T1 and T2 sequences. DCE-MRI datasets with contoured gross target volumes (GTVs) were imported for image analysis into MIM software (MIM Corporation, Cleveland, Ohio). The NMF (non-negative matrix factorization) algorithm was implemented in MIM. There are three characteristic patterns of signal-vs-time curves that UPR identifies within each GTV-namely, Pattern A, which identifies subvolumes with fast contrast uptake and fast washout; Pattern B for subvolumes with delayed uptake and washout; and Pattern C, with slow or no contrast uptake.

RESULTS: The aforementioned three patterns identified corresponding subvolumes in each GTV. The mean GTV volume was 56.8 cc (range: 22–146.6 cc). Subvolumes for each of Patterns A, B, and C averaged 31% ± 3.6%, 30% ± 5.3%, and 39% ± 8.4% of the total GTV, respectively. The standard deviations showed relatively tight dispersion of these values around their respective means, suggesting relative constancy throughout the patients studied. Although no clear geographically consistent relationship between the subvolumes emerged, necrotic regions identified by computed tomography (CT) or MRI were consistently located within Pattern C subvolumes. All three patterns were qualitatively identical to those reported in a previously published preclinical study by our group, wherein Pattern B subvolumes corresponded to regions of tumor hypoxia on 18F-fluoro-misonidazole (MISO) images and radiolabeled pimonidazole histological slices.

CONCLUSION: UPR is a novel technique that has been developed in a preclinical tumor model and that is potentially applicable in HNCs. This exploratory study appears consistently to identify subvolumes within the GTV that may have therapeutic implications and that may be promising areas for further research (eg, correlation with hypoxia and clinical outcome).

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content